第54届美国血液学会年会骨髓增生异常综合征研究领域亮点报道

Highlights of myelodysplastic syndromes in the 54th ASH annual meeting

介绍第54届美国血液学会（ASH）年会有关骨髓增生异常综合征（MDS）研究领域的几个亮点。第二代测序揭示了MDS患者的基因突变谱系。为提高去甲基化药物治疗MDS患者的有效病例数和进一步改善疗效期，一些预测疗效的新细胞遗传学和分子生物学参数得以不断被确认。

Highlights of myelodysplastic symdromes （MDS） in the 54th ASH annual meeting were reviewed. Next-Generation Sequencing has revealed the spectrum of gene mutations in MDS patients. Some new molecular and cytogenetic parameters for increasing the number of responding patients and to further improve the durability of response to hypomethylating agents were comfirmed.